Clinical Trial Search

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants

Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants

Primary: Number of Participants (Par.) With Response as Assessed by the Investigator — 31 participants

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Complete Response Rate (CRR) — 73 Percentage of patients

Primary: Number of Participants With Unconfirmed Response (Complete Response or Partial Response) and Unconfirmed Complete Response — 437; 238 Participants

Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14

Primary: B-cell Density Stained Area — 0.027 mm^2/mm^2

Primary: Overall ObjectiveResponse (ORR) Rate — 0; 7; 19; 4 participants

Primary: Number of Participants With at Least One Dose Limiting Toxicity (DLT) — 3; 1; 0; 0 Participants

Primary: Number of Participants (Par.) With Confirmed Response as Assessed by the Investigator — 21; 8 participants

Primary: Overall Response Rate as Assessed According to the"Revised Response Criteria for Malignant Lymphoma" (Cheson 2007). — 5; 2; 7; 1 Participants

Primary: Number of Participants With Confirmed Response, Including Participants With Complete Response (CR), Clinical Complete Response (CCR), and Partial Response (PR) — 72…

Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants

Primary: Number of Participants (Par.) During Initial Treatment Exposed to the Indicated Dose Levels of the Therapeutic Dose (TD), Re-dose, and Total Dose (TD + Re-dose) — 6; 1…

Primary: Overall Response Rate (ORR) — 46.2 percentage of participants — p=0.0044

Primary: Progression Free Survival — 389; 334 days — p=0.039

Primary: Efficacy: Complete Response Rate (CRR) — 9.5 percentage of patients

Primary: Complete Response (CR) and Complete Response Unconfirmed (CRu) — 20.0; 5.7; 24.3; 7.1 percentage of randomized patients

Primary: 1 Year Progression-free Survival Rate — 0.74 percentage of participants

Primary: Overall Response Rate (Complete Response and Partial Response) After Three Inductions Cycles of Treatment. — 71 percentage of patients

Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 0 Participants

Primary: Overall Response Rate — 40; 55; 29 percentage of patients

Primary: 2-year Progression-free Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM) — 62…

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 29; 49; 11; 15 participants

Primary: Progression-free Survival at 2 Years — 15 Participants

Primary: Number of Participants With the Indicated Grade 4 Hematology Toxicities Following Iodine-131 Anti-B1 Antibody — 1; 1; 1; 1 participants

Primary: Proportion of Responses (Complete Response or Partial Response) — 19.0; 42.9 percentage of participants

Primary: Overall Response Rate — 81.8 Percentage